| Anemia | Blood and lymphatic system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0006 affected50 at risk
- EG0016 affected50 at risk
|
| Anaemia macrocytic | Blood and lymphatic system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Blood loss anaemia | Blood and lymphatic system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0010 affected50 at risk
|
| Coagulopathy | Blood and lymphatic system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Hilar lymphadenopathy | Blood and lymphatic system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Hypercoagulation | Blood and lymphatic system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Leukocytosis | Blood and lymphatic system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0003 affected50 at risk
- EG0014 affected50 at risk
|
| Leukopenia | Blood and lymphatic system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0014 affected50 at risk
|
| Thrombocytosis | Blood and lymphatic system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Atrial fibrillation | Cardiac disorders | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0015 affected50 at risk
|
| Bradycardia | Cardiac disorders | MedDRA 23.0 | Systematic Assessment | | - EG0004 affected50 at risk
- EG0012 affected50 at risk
|
| Cardiomyopathy | Cardiac disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Sinus tachycardia | Cardiac disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Supraventricular tachycardia | Cardiac disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Tachycardia | Cardiac disorders | MedDRA 23.0 | Systematic Assessment | | - EG0005 affected50 at risk
- EG0011 affected50 at risk
|
| Ventricular tachycardia | Cardiac disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Cataract | Eye disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Dry eye | Eye disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Eye disorder | Eye disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Abdominal pain | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Constipation | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0004 affected50 at risk
- EG0018 affected50 at risk
|
| Diarrhoea | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Dry mouth | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Dyspepsia | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Dysphagia | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Flatulence | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0012 affected50 at risk
|
| Gastrooesophageal reflux disease | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Haemorrhoids | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Ileus | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0003 affected50 at risk
- EG0010 affected50 at risk
|
| Impaired gastric emptying | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Melaena | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Mouth ulceration | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Nausea | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Post-tussive vomiting | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Rectal haemorrhage | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Stomatitis | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Swollen tongue | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0010 affected50 at risk
|
| Catheter site haemorrhage | General disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Chest pain | General disorders | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0011 affected50 at risk
|
| Fatigue | General disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Generalised oedema | General disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Oedema | General disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Oedema peripheral | General disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Pyrexia | General disorders | MedDRA 23.0 | Systematic Assessment | | - EG0003 affected50 at risk
- EG0011 affected50 at risk
|
| Tachyphylaxis | General disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Hepatic steatosis | Hepatobiliary disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Cytokine release syndrome | Immune system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Bacterial diarrhoea | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Clostridium difficile colitis | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Cystitis | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Diverticulitis | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Enterococcal bacteraemia | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Fungaemia | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Herpes dermatitis | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Labyrinthitis | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Oesophageal candidiasis | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Oral candidiasis | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Oral herpes | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Oropharyngeal candidiasis | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Pneumonia | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0013 affected50 at risk
|
| Pneumonia bacterial | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0004 affected50 at risk
- EG0011 affected50 at risk
|
| Pneumonia escherichia | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Pneumonia klebsiella | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0011 affected50 at risk
|
| Pneumonia serratia | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Salpingitis | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Septic shock | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Staphylococcal bacteraemia | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Urinary tract infection | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0012 affected50 at risk
|
| Vulvovaginal candidiasis | Infections and infestations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Perineal injury | Injury, poisoning and procedural complications | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Procedural hypotension | Injury, poisoning and procedural complications | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Skin abrasion | Injury, poisoning and procedural complications | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0012 affected50 at risk
|
| Skin laceration | Injury, poisoning and procedural complications | MedDRA 23.0 | Systematic Assessment | | - EG0003 affected50 at risk
- EG0010 affected50 at risk
|
| Vascular access complication | Injury, poisoning and procedural complications | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Vulvovaginal injury | Injury, poisoning and procedural complications | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Alanine aminotransferase increased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Aspartate aminotransferase increased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Blood albumin decreased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Blood creatinine decreased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Blood lactate dehydrogenase increased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Blood pH increased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Blood phosphorus decreased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Blood potassium increased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Blood pressure increased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Blood sodium decreased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Body temperature decreased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Body temperature increased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0011 affected50 at risk
|
| C-reactive protein increased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Carbon dioxide increased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Coombs direct test positive | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0003 affected50 at risk
- EG0010 affected50 at risk
|
| Electrocardiogram QT prolonged | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Eosinophil count increased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0010 affected50 at risk
|
| Fibrin D dimer increased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Haematocrit decreased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Haemoglobin decreased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Heart rate abnormal | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Heart rate increased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Neutrophil count increased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0010 affected50 at risk
|
| Occult blood positive | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Platelet count decreased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0011 affected50 at risk
|
| Platelet count increased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Red blood cell count decreased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Respiratory rate increased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0004 affected50 at risk
- EG0012 affected50 at risk
|
| Serum ferritin increased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Transaminases increased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0010 affected50 at risk
|
| White blood cell count increased | Investigations | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0010 affected50 at risk
|
| Diabetes mellitus | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Hypercalcaemia | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Hyperglycaemia | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0010 affected50 at risk
|
| Hyperkalaemia | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment | | - EG0003 affected50 at risk
- EG0018 affected50 at risk
|
| Hypermagnesaemia | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0012 affected50 at risk
|
| Hypernatraemia | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment | | - EG0004 affected50 at risk
- EG0012 affected50 at risk
|
| Hyperphosphataemia | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Hypertriglyceridaemia | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Hypoalbuminaemia | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Hypocalcaemia | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0013 affected50 at risk
|
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0014 affected50 at risk
|
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment | | - EG0005 affected50 at risk
- EG00112 affected50 at risk
|
| Hypomagnesaemia | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Hyponatraemia | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment | | - EG0006 affected50 at risk
- EG0014 affected50 at risk
|
| Hypophosphataemia | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Lactic acidosis | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Malnutrition | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Metabolic acidosis | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Compartment syndrome | Musculoskeletal and connective tissue disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Limb discomfort | Musculoskeletal and connective tissue disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Musculoskeletal pain | Musculoskeletal and connective tissue disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Neck pain | Musculoskeletal and connective tissue disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Spinal pain | Musculoskeletal and connective tissue disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Dizziness | Nervous system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Encephalopathy | Nervous system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0004 affected50 at risk
- EG0010 affected50 at risk
|
| Headache | Nervous system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0011 affected50 at risk
|
| Hypoaesthesia | Nervous system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Metabolic encephalopathy | Nervous system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Paraesthesia | Nervous system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Seizure | Nervous system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Syncope | Nervous system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Tension headache | Nervous system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Toxic encephalopathy | Nervous system disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Agitation | Psychiatric disorders | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0012 affected50 at risk
|
| Anxiety | Psychiatric disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0013 affected50 at risk
|
| Delirium | Psychiatric disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Insomnia | Psychiatric disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0012 affected50 at risk
|
| Intensive care unit delirium | Psychiatric disorders | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0010 affected50 at risk
|
| Mental status changes | Psychiatric disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Post-traumatic stress disorder | Psychiatric disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Sleep disorder | Psychiatric disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Acute kidney injury | Renal and urinary disorders | MedDRA 23.0 | Systematic Assessment | | - EG0004 affected50 at risk
- EG0011 affected50 at risk
|
| Haematuria | Renal and urinary disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Renal failure | Renal and urinary disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Postmenopausal haemorrhage | Reproductive system and breast disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Vulval disorder | Reproductive system and breast disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Acute respiratory distress syndrome | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Acute respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0011 affected50 at risk
|
| Aspiration | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0003 affected50 at risk
- EG0014 affected50 at risk
|
| Haemoptysis | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Hypercapnia | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0011 affected50 at risk
|
| Hypoxia | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Nasal septum ulceration | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Pleuritic pain | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Pneumomediastinum | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0003 affected50 at risk
- EG0012 affected50 at risk
|
| Pneumothorax | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0013 affected50 at risk
|
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0003 affected50 at risk
- EG0014 affected50 at risk
|
| Pulmonary hypertension | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Pulmonary oedema | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Respiratory acidosis | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Respiratory disorder | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Rhinorrhoea | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Decubitus ulcer | Skin and subcutaneous tissue disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Dry skin | Skin and subcutaneous tissue disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Rash | Skin and subcutaneous tissue disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Skin disorder | Skin and subcutaneous tissue disorders | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0010 affected50 at risk
|
| Skin maceration | Skin and subcutaneous tissue disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Subcutaneous emphysema | Skin and subcutaneous tissue disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Tracheostomy | Surgical and medical procedures | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Deep vein thrombosis | Vascular disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Distributive shock | Vascular disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Haematoma | Vascular disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0011 affected50 at risk
|
| Hypertension | Vascular disorders | MedDRA 23.0 | Systematic Assessment | | - EG0002 affected50 at risk
- EG0012 affected50 at risk
|
| Hypotension | Vascular disorders | MedDRA 23.0 | Systematic Assessment | | - EG00011 affected50 at risk
- EG00110 affected50 at risk
|
| Jugular vein thrombosis | Vascular disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Microembolism | Vascular disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Shock | Vascular disorders | MedDRA 23.0 | Systematic Assessment | | - EG0001 affected50 at risk
- EG0010 affected50 at risk
|
| Thrombophlebitis superficial | Vascular disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|
| Vasodilatation | Vascular disorders | MedDRA 23.0 | Systematic Assessment | | - EG0000 affected50 at risk
- EG0011 affected50 at risk
|